Market Place
Sourcing Support
ARTbio Partners with 3B Pharma for Alpha Radioligand Therapy
14 Nov 2024 //
PR NEWSWIRE
ARTBIO Partners with 3B Pharma on Alpha Radioligand for Tumors
13 Nov 2024 //
PR NEWSWIRE
FogPharma, ARTBIO Collaborate On Helicon Alpha-Particle Radioligand Therapies
14 May 2024 //
BUSINESSWIRE
FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs)
14 May 2024 //
BUSINESSWIRE
ARTBIO, Nucleus RadioPharma Collaborating On Radioisotope Products
07 May 2024 //
BUSINESSWIRE
ARTBIO and PharmaLogic Announce Agreement for Candidate AB001
12 Jan 2024 //
PR NEWSWIRE
SpectronRx and ARTBIO Join Forces to Develop Clinical Supply of AB001
09 Jan 2024 //
BUSINESSWIRE
ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing
07 Dec 2023 //
PR NEWSWIRE
Investors pour $90M onto ARTBIO`s palette 6 months after launch
07 Dec 2023 //
FIERCE BIOTECH
ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer
05 Oct 2023 //
PR NEWSWIRE
ARTBIO and SpectronRx Enter a Collaboration to Manufacture Components of AlphaDirect Technology
24 Jul 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.